Undisclosed FGFR2b-targeting ADC / Shanghai Ailux Biotechnology, XtalPi - LARVOL DELTA

Preclinical evaluation of a novel and highly differentiated FGFR2b-targeting ADC with low risk of ocular toxicity (AACR 2026) - "Bemarituzumab, an ADCC-enhanced FGFR2b antagonist, has demonstrated efficacy in patients with FGFR2b-overexpressing G/GEJ cancer. Together, these data demonstrate preclinical efficacy and low risk of ocular toxicity of a FGFR2-targeting ADC utilizing ALX007 as a highly differentiated antibody backbone. Further development for the treatment of FGFR2b-expressing tumors is warranted."

ADC • Preclinical • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • FGF10 • FGF7 • FGFR2

SCR-A002, a novel FGFR2b-targeting ADC for solid tumors (AACR 2025) - "Background: FGFR2b (fibroblast growth factor receptor 2 IIIb), an isoform of transmembrane tyrosine kinase FGFR family, is overexpressed in various cancers, including gastric, esophageal, breast, hepatocellular, pancreatic, ovary, uterine, cervical, endometrial, lung, colorectal cancers. SCR-A002 showed remarkable anti-tumor efficacy in preclinical data, suggesting that SCR-A002 is expected to provide a new treatment option as single agent or combo with SoC for patients with FGFR2b-overexpressing solid tumor."

ADC • Colorectal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • FGFR2

Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b-targeting ADC, for the treatment of FGFR2b-expressing cancer (AACR 2025) - P1 | "Indeed, the clinical benefit of targeting FGFR2b has been demonstrated by Bemarituzumab, an Fc-enhanced monoclonal antibody in combination with chemotherapy in first-line FGFR2b-expressing gastric cancer. With its differentiated targeting strategy, BG-C137 is not only a first-in-class FGFR2b ADC but also holds the potential to pursue the best-in-class opportunity in FGFR2b targeting treatments. Together, these observations support the clinical development of BG-C137 for the treatment of FGFR2b-expressing tumors (ClinicalTrials.gov ID NCT06625593)."

ADC • Preclinical • Gastric Cancer • Oncology • Solid Tumor • FGFR2